Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight management and diabetes treatment. Offering a dual-action mechanism targeting GLP-1 and GIP receptors,

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ingredient in Wegovy and Ozempic) will go off-patent in India, allowing local firms to introduce cheaper alternatives.

While experts welcomed Mounjaro's launch, they stressed the importance of responsible prescribing to prevent misuse of the drug used for the treatment of type 2 diabetes and obesity.